Join us for a virtual investor event on updates to the Erasca pipeline. The Erasca leadership team will discuss its pipeline targeting RAS/MAPK pathway-driven cancers, with a focus on the ERAS-007 program. ERAS-007 is a potentially best-in-class ERK1/2 inhibitor in Phase 1b/2 clinical development for the treatment of RAS/MAPK pathway-altered solid tumors.

A live question and answer session will follow the formal presentation.